-cir-
tadocizumab
erlizumab
tislelizumab
ravulizumab
abagovomab
gevokizumab
olaratumab
brolucizumab
pidilizumab
tisotumab
antimonoclonal
ABO antibodies
cibisatamab
retifanlimab
dinutuximab
sintilimab
ziltivekimab
toripalimab
solitomab
muromonab
vanucizumab
guselkumab
evolocumab
sasanlimab
olendalizumab
zenocutuzumab
pozelimab
alirocumab
cytophilic antibody
anaphylactic antibody
autoagglutinin
cytotropic antibody
countercorrelated
dorlixizumab
immunoglobulin G
anticorrelate
-mul-
complement
teplizumab
caplacizumab
antiheart
-lim-
antiphospholipid antibody
-o-
-mab
antisubstance
soravtansine
serospecific
otelixizumab
amlitelimab
monoantibody
bivatuzumab
antinucleotide
intetumumab
immunovascular
tenatumomab
carlumab
conatumumab
naptumomab estafenatox
cergutuzumab
imciromab
intrabody
drozitumab
heteroclitic
lexatumumab
antiplasma
cilgavimab
agonistic monoclonal antibody
Ab
antipolyvalent
ipilimumab
antiserum
ozogamicin
glembatumumab
pexelizumab
itolizumab
endostatin
ozoralizumab
autoantibody
antigenomic
siltuximab
-ab
robatumumab
avdoralimab
immunoliposome
durvalumab
seroconversion
zanolimumab
inotuzumab
pancytokeratin
antiantibody
sotrovimab
mapatumumab
polyantibody
brentuximab
duligotuzumab
myomegalin
immunoreactant
leronlimab